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Background: Cancer is one of the most dreaded diseases and it is a leading cause of mankind death worldwide.
Recent reports documented a remarkable antiproliferative activity of isatin nucleus against various cancer cell lines.
The current work describes the antiproliferative activity of Schiff bases of combinatorial mixtures of the isatin
derivatives M1-M22 as well as the individual compounds 1-11(A-K) of these combinatorial mixtures.
Results: The designed combinatorial library composed from eleven hydrazides A-K and eleven isatin derivatives
1-11 has been synthesized to formally generate 22 mixtures, M1-M22 of 121 Schiff bases, and their antiproliferative
activity against K562 chronic myelogenous leukemia cells was evaluated. The indexed method of analysis of the
prepared library was applied to elucidate the active components in the tested mixtures M1-M22. The predictions
from the crossing procedure was validated through evaluation of the antiproliferative activity of individual
compounds 1-11(A-K) of the library. Individual compounds 1-11(A-K) were also evaluated against the
non-tumorigenic MCF-12A cell line to investigate their selectivity. A pharmacophore model was developed to
further optimize the antiproliferative activity among this series of compounds.
Conclusions: Variable antiproliferative activity was revealed with the investigated mixtures M1-M22 and the
individual compounds 1-11(A-K). Most of the tested mixtures and several individual Schiff bases displayed high
potency with IC50 values in the low micromolar range. A considerable selectivity of some individual compounds to
the tumorigenic K562 cell line compared with the non-tumorigenic MCF-12A cell line was observed as indicated by
their selectivity index (SI).
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Cancer is one of the most dreaded diseases of mankind.
It is a leading cause of death throughout the world, and
currently, one in 4 deaths in the United States is due to
cancer [1]. More than ten million new cancer cases
occur annually, roughly half of which is in the developed
countries, and the disease causes over six million deaths
a year [2,3]. Unlimited and uncontrolled cell prolifera-
tion is obviously characteristics of tumor cells [4].
Despite several decades of intensive research, the long-
term outlook for patients with aggressive cancer remains
discouraging, and there is a need for innovative
approaches to design anticancer drugs with reduced* Correspondence: fadl@ksu.edu.sa
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distribution, and reproduction in any mediumtoxicity and improved therapeutic indices [5,6]. In recent
years, compounds containing hydrazide or hydrazone
moieties are attractive target compounds for new drug
development because of their potentially versatile bio-
logical activities involving antiproliferative activities [7,8].
Several studies have been devoted to the antiproliferative
activity of aroylhydrazone derivatives [7,9-12]. It was sug-
gested that the antiproliferative activity of these hydra-
zones may be attributed to inhibition of kinases [13-15],
or through generation of radicals and dissipation of the
mitochondrial membrane potential [16].
Furthermore, there are significant reasons for investi-
gating the antiproliferative activity of Schiff base deriva-
tives of indolin-2,3-dione (isatin) as recent reports
documented a remarkable antiproliferative activity of
isatin nucleus against various cancer cell lines [17-22].
Isatins have multiple molecular mechanisms to exert
their anticancer activity. Among which tyrosine kinaseentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(CDKs) by binding to the ATP pocket and/or caspase in-
hibition [23-25].
In continuation to our synthetic work on Schiff bases
of isatin with potential biological activity [26-32], the
current work describes the antiproliferative activity of
Schiff bases of combinatorial mixtures of the isatin
derivatives M1-M22 as well as the individual com-
pounds 1-11(A-K) of these combinatorial mixtures.
Moreover, Ligand based pharmacophore modeling of
these Schiff bases was conducted to evaluate the com-
mon features essential for activity and the hypothetical
geometries adopted by these ligands in their most active
conformers were undertaken.
Results and discussion
The designed combinatorial library mixtures M1-M22
of the Schiff bases as well as its individual compounds
A-K(1-11) were already published [27,29,30]. They were
obtained either by conventional or microwave assisted
methods and are summarized in Table 1.
In vitro antiproliferative activity of the combinatorial
mixtures M1-M22 was carried out by use of WST-1 re-
agent for determination of IC50 for each mixture against
K562 chronic myelogenous leukemia cells according to
the protocol mentioned in the experimental section and
results are given in Table 1. Variable antiproliferative ac-
tivity was observed with the investigated mixtures in the
following decreasing order: M6>M22>M5>M15>
M7>M4>M1>M3>M9>M18>M2=M10>M16
>M11>M19>M14 with IC50 range values from 4.48
to 22.6 μM. Other mixtures did not show significant
antiproliferative activity against MCF-12A cell line
(IC50> 100 μM). The most active mixtures in the first
set are mixtures M5-M7 whereas in the second set are
mixtures M15, M18, and M22. The indexed method of
analysis of the prepared library was applied to elucidate
the active components in the tested mixtures M1-M22.
Intersection of the active rows M1-M7, and M9-M11
with the active columns M12, M14-M16, M18, M19,
and M22 gave the location of the possible active compo-
nents in these mixtures, distinguished by bold cell bor-
ders (see Additional file 1).
In order to confirm the reliability of the predictions
from the crossing procedure, the synthesized individual
compounds A-K(1-11) were also investigated against
K562 cell line. From the scattered data given in Table 2,
it was difficult to determine precisely the essential moi-
eties in compounds 1-11(A-K) required to elicit antipro-
liferative activity. A general conclusion, however, can be
made about the SAR in the synthesized series of hydra-
zones 1-11(A-K) that the integrated molecular structure
features are responsible for the elucidated antiprolifera-
tive activity irrespective of the building blocksincorporated in individual molecules. According to the
displayed antiproliferative activity of the title compounds
1-11(A-K) they can be divided into: highly active can-
didates with IC50< 10 μM (B5, D2-D11, E1-E4, E6, E7,
E9, E10, F1, F8-F11, G1-G7, G10, H2, H5, H6, H11,
I2, I6, J5, and J6), moderately active candidates with
IC50< 20 μM (B3, B9, B10, C1, C3, D1, D3, E5, E8,
E11, F2-F7, G8, H1, I1, I3, I4, I10, J4, and J7), weekly
active with IC50 ~ 20< 100 μM (A1-A4, A9, B1, B2,
B4, B7, B8, B11, C2, C4, C5, H4, H7-H10, I5, I9, J2,
J8, J9, and K10) and inactive with IC50> 100 μM (rest
of the compounds). It is clear that series A with isonico-
tinic acid hydrazide, B with nicotinic acid hydrazide, C
with furan-2-carboxylic acid hydrazide and K with nali-
dixic acid hydrazide have the least contribution in anti-
proliferative activity.
Surprisingly, antiproliferative activity prediction of the in-
dividual compounds from the intersection of M1-M11 and
M12-M22 was not consistent with the results achieved
from practical investigations of individual compounds par-
ticularly in case of A and K series. This may be attributed
to the additive contribution of the active components in
their mixture that are effective than that tested separately.
To evaluate the selectivity of these individual com-
pounds on the tumorigenic cells, their cytotoxicity was
measured by cell growth inhibition assay against MCF-
12A cell line. The MCF-12A cell line is a non-tumorigenic
epithelial cell line established from tissue taken at reduc-
tion mammoplasty from a nulliparous patient with fibro-
cystic breast disease that contained focal areas of
intraductal hyperplasia. The general in vitro cytotoxic
evaluation of these synthesized compounds was carried
out also by use of WST-1 reagent for determination of
IC50 for each compound according to the protocol men-
tioned in the experimental section and results are given in
Table 2. The selectivity index (SI) which represents IC50
for normal cell line/IC50 for cancerous cell line. As the SI
demonstrates the differential activity of a compound, the
greater the SI value is, the more selective it is. Variable se-
lectivity was observed with the different investigated com-
pounds (Table 2). Though it is difficult to contribute the
selectivity pattern to either of the building blocks, the E
series with benzofuran moiety revealed good selectivity
pattern. Among the highly active candidates, compounds
D2, D10, D11, F9, F10, F11, G3-G7, G10, H2, H5, J5,
and J6 were the least selective but the others revealed rea-
sonable selectivity toward the tumorigenic cell.
Pharmacophore modeling
Elucidation of the binding approaches for the synthesized
compounds is suggested based on finding the active struc-
tures. Table 1 shows the structure of the training set com-
pounds (A1, A9, B1, B5, B9, C3, D5, E3, E5, F3, F5, G3,
G5, H5, I3, and J5) as well as the test set compounds (B7,
Table 1 Antiproliferative evaluation results of the synthesized combinatorial mixtures M1-M22 and schematic representation of an orthogonal deconvolution
for prediction of the active compounds

































































































A11 B11 C11 D11 E11 F11 G11 H11 I11 J11 K11 M11 14.57 ± 0.05
Set 2 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22
IC50
a (μM) 12.02±0.026 b 22.6±0.038 4.85±0.018 10.1±0.05 b 9.64±0.003 21.06±0.02 b b 4.51±0.003
aIC50: concentration of the compound (μM) producing 50 % cell growth inhibition after 48 h of compound exposure, as determined by the WST-1 assay. Each experiment was run at least two times, and the results are













Table 2 Cytotoxicity activity of the synthesized individual compounds 1-11(A-K)
Compound/IC50 (μM)
Compound A1 B1 C1 D1 E1 F1 G1 H1 I1 J1 K1
K562 cell line 20.04 ± 0.07 42.3 ± 0.03 13.47 ± 0.038 11.5 ± 0.01 6 ± 0.007 7.7 ± 0.02 5.66 ± 0.11 15.37 ± 0.02 11.59 ± 0.034 > 100 > 100
MCF-12A cell line 69.23 ± 0.123 49.39 ± 0.16 > 300 > 300 > 300 64.31 ± 0.026 16.61 ± 0.181 37.12 ± 0.27 > 300 > 300 > 300
SI 3.45 1.17 > 22.27 > 26.1 > 50.00 8.4 2.9 2.42 > 25.88 NA NA
Compound A2 B2 C2 D2 E2 F2 G2 H2 I2 J2 K2
K562 cell line 49.13 ± 0.095 20.19 ± 0.09 29.82 ± 0.139 8.3 ± 0.003 7.76 ± 0.07 12.9 ± 0.002 5.72 ± 0.1 8.05 ± 0.035 8.67 ± 0.027 23.32 ± 0.32 > 100
MCF-12A cell line 32.55 ± 0.073 > 300 > 300 14.78 ± 0.4 > 300 31.39 ± 0.096 16.62 ± 0.182 11.67 ± 0.003 > 300 17.91 ± 0.62 > 300
SI 0.66 > 14.86 > 10.06 1.8 > 38.66 2.4 2.9 1.45 > 34.60 0.77 NA
Compound A3 B3 C3 D3 E3 F3 G3 H3 I3 J3 K3
K562 cell line 32.37 ± 0.074 19.35 ± 0.019 14.86 ± 0.055 13.86 ± 0.01 7.13 ± 0.009 14 ± 0.08 9.88 ± 0.41 > 100 15.81 ± 0.11 19.75 ± 0.08 > 100
MCF-12A cell line 27.06 ± 0.272 > 300 > 300 258.09 ± 0.03 > 300 8.71 ± 0.17 13.22 ± 0.034 97.36 ± 0.062 27.87 ± 0.07 > 300 83.8± 0.039
SI 0.84 > 15.50 > 20.19 18.6 > 42.08 0.62 1.3 NA 1.76 > 15.19 NA
Compound A4 B4 C4 D4 E4 F4 G4 H4 I4 J4 K4
K562 cell line 38.88 ± 0.138 51.51 ± 0.09 30.96 ± 0.2 9.98 ± 0.009 7.5 ± 0.03 16.28 ± 0.015 8.43 ± 0.163 24.21 ± 0.023 11.57 ± 0.051 14.52 ± 0.08 > 100
MCF-12A cell line 9.39 ± 0.152 > 300 > 300 > 300 > 300 50.85 ± 0.048 12.50 ± 0.216 > 300 > 300 12.74 ± 0.32 78.29 ± 0.31
SI 0.24 > 5.82 > 9.69 > 30 > 40.00 3.1 1.5 > 12.39 > 25.93 0.88 NA
Compound A5 B5 C5 D5 E5 F5 G5 H5 I5 J5 K5
K562 cell line > 100 7.3 ± 0.01 23.9 ± 0.26 8.67 ± 0.007 10.3 ± 0.001 10.4 ± 0.044 6.5 ± 0.001 5.88 ± 0.004 24.11 ± 0.255 6.99 ± 0.005 > 100
MCF-12A cell line 39.74 ± 0.073 > 300 > 300 80.05 ± 0.40 > 300 39.09 ± 0.24 9.1 ± 0.003 7.35 ± 0.094 > 300 5.6 ± 0.003 > 300
SI NA > 41.10 > 12.55 9.2 > 29.13 3.8 1.4 1.25 > 12.44 0.80 NA
Compound A6 B6 C6 D6 E6 F6 G6 H6 I6 J6 K6
K562 cell line > 100 > 100 > 100 8.87 ± 0.017 9.58 ± 0.03 13.5 ± 0.03 6.62 ± 0.22 6.49 ± 0.017 8.55 ± 0.06 7.19 ± 0.051 > 100
MCF-12A cell line 13.91 ± 0.003 > 300 > 300 134.18 ± 0.142 > 300 9.6 ± 0.15 13.05 ± 0.20 34.77 ± 0.062 26.15 ± 0.14 10.16 ± 1.2 > 300
SI NA NA NA 15.1 > 31.32 0.71 2 5.36 3.06 1.41 NA
Compound A7 B7 C7 D7 E7 F7 G7 H7 I7 J7 K7
K562 cell line > 100 47.25 ± 0.027 > 100 9.1 ± 0.026 8.9 ± 0.02 12.86 ± 0.01 7.68 ± 0.34 23.67 ± 0.39 > 100 18.02 ± 0.13 > 100
MCF-12A cell line 11.03 ± 0.151 > 300 > 300 > 300 > 300 11.39 ± 0.25 12.98 ± 0.439 73.18 ± 0.072 > 300 > 300 61.34 ± 0.01
SI NA > 6.35 NA > 33 > 33.71 0.89 1.7 3.09 NA > 16.65 NA
Compound A8 B8 C8 D8 E8 F8 G8 H8 I8 J8 K8
K562 cell line > 100 27.23 ± 0.092 > 100 6.9 ± 0.001 10.34 ± 0.015 6.99 ± 0.007 15.12 ± 0.48 40.65 ± 0.24 > 100 45.51 ± 0.46 > 100
MCF-12A cell line 10.54 ± 0.157 > 300 > 300 > 300 > 300 21.29 ± 0.104 > 300 > 300 > 300 > 300 > 300
SI NA > 11.02 NA > 43.5 > 29.01 3 > 19.8 > 7.38 NA > 6.59 NA













Table 2 Cytotoxicity activity of the synthesized individual compounds 1-11(A-K) (Continued)
K562 cell line 90.67 ± 0.19 17.42 ± 0.05 > 100 6.2 ± 0.01 9.77 ± 0.01 6.77 ± 0.01 > 100 26.72 ± 0.38 31.19 ± 0.004 52.05 ± 0.15 > 100
MCF-12A cell line 14.48 ± 0.647 > 300 > 300 > 300 > 300 13.14 ± 0.114 > 300 > 300 > 300 > 300 5.88 ± 0.11
SI 0.16 > 17.22 NA > 48.4 > 30.71 1.9 NA > 11.23 > 9.62 > 5.76 NA
Compound A10 B10 C10 D10 E10 F10 G10 H10 I10 J10 K10
K562 cell line > 100 17.88 ± 0.062 > 100 8.9 ± 0.43 8.66 ± 0.06 6.3 ± 0.005 8.43 ± 0.18 23.34 ± 0.19 19.14 ± 0.07 > 100 88.85 ± 0.26
MCF-12A cell line 8.33 ± 0.044 > 300 > 300 12.57 ± 0.089 > 300 11.01 ± 0.11 14.19 ± 0.175 32.86 ± 0.065 > 300 > 300 51.02 ± 0.04
SI NA > 16.78 NA 1.4 > 34.64 1.7 1.7 1.41 > 15.67 NA 0.57
Compound A11 B11 C11 D11 E11 F11 G11 H11 I11 J11 K11
K562 cell line > 100 39.24 ± 0.006 > 100 9.11 ± 0.23 13.65 ± 0.52 5.92 ± 0.002 > 100 8.46 ± 0.27 > 100 > 100 > 100
MCF-12A cell line 7.88 ± 0.01 > 300 > 300 10.15 ± 0.072 > 300 12.46 ± 0.053 97.93 ± 0.16 29.84 ± 0.17 > 300 > 300 28.31 ± 0.14
SI NA > 7.65 NA 1.1 > 21.98 2.1 NA 3.53 NA NA NA
aIC50: concentration of the compound (μM) producing 50 % cell growth inhibition after 48 h of compound exposure, as determined by the WST-1 assay. Each experiment was run at least two times, and the results are













Table 4 Output for Hypo1 mapping and predictive model
of training set compounds
Compds IC50 (μM) p(IC50 × 10




A1 20.04 1.70 74.84 1.47 0.23
Figure 1 Proposed pharmacophore model for antiproliferative
activity (red, HBA; yellow, hydrophobic; green, HBD).
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http://journal.chemistrycentral.com/content/6/1/49B8, B10, D2-D4, E2, F2, H8, J4, and J8). Based on the as-
sumption that the active compounds bind in a similar fash-
ion at the active site. Ligandscout program [33] was
employed to evaluate the common features essential for
antiproliferative activity and the hypothetical geometries
adopted by these ligands in their most active forms. Thus,
these compounds were submitted for pharmacophore
model generation based on the shared chemical features.
Diverse conformations within 20 kcal/mol energy range
were generated and submitted to the alignment procedure.
The successful pharmacophore run resulted in gener-
ation of 10 hypotheses (Hypo1-10, Table 3). Hypo1-7
composed of two hydrophobes, three hydrogen bond
acceptors and two hydrogen bond donors. According to
its highest rank score and mapping into all training set
molecules, hypo1 was considered statistically as the best
hypothesis and was selected for further investigation and
analysis. The top-ranked chemical feature-based pharma-
cophore model identified in this study is shown in Figure 1.
This pharmacophore model contains seven chemical fea-
tures: two hydrophobes (orange), three hydrogen bond
acceptors (red) and two hydrogen bond donors (green).
All the training set and test set compounds were
mapped onto hypo1 with scoring the orientation of a
mapped compound within the hypothesis features using
a “fit value” score. As a quick and primary validation of
hypo1, mapping of the compounds found to show a
good agreement between the fit value and the biological
activity (Tables 4 and 5, Figures 2 and 3).
Initial investigation of the results shown in Tables 4
and 5 revealed a moderate correlation between the fit
value and the biological activity of each of the tested
compounds. The highly active compounds showed a
range of fit value of 81.54-80.03 where the moderately
active derivatives showed a lower fit value average of
74.0. This initial correlation encouraged us to generate aTable 3 Summary of the generated pharmacophores of
the Antiproliferative activities of the synthesized Schiff
bases against MCF-12A cell line











*H hydrophobic, R aromatic ring, A hydrogen bond acceptor, D hydrogen
bond donor.linear model based on “fit value” to predict the biological
activity of the compounds under investigation. The gen-
erated model (Equation 1) showed good statistics and
was used successfully to calculate the activity of the
tested compounds (Table 4).
pIC50¼7:4164 fit valueþ65:291 ð1Þ
n=16, st. error = 0.181, R= 0.834, R² = 0.696 Where n:
number of compounds; R: multiple correlation coefficientA9 90.67 1.04 74.46 1.44 -0.40
B1 42.30 1.37 74.84 1.47 -0.10
B5 7.30 2.14 81.42 2.09 0.05
B9 17.42 1.76 74.46 1.44 0.32
C3 14.86 1.83 80.39 1.99 -0.16
D5 8.67 2.06 81.54 2.10 -0.04
E3 7.13 2.15 80.37 1.99 0.16
E5 10.30 1.99 80.42 2.00 -0.01
F3 14.00 1.85 80.37 1.99 -0.14
F5 10.40 1.98 80.42 2.00 -0.02
G3 9.88 2.01 80.44 2.00 0.01
G5 6.50 2.19 81.52 2.10 0.09
H5 5.88 2.23 81.54 2.10 0.13
I3 15.81 1.80 80.44 2.00 -0.20
J5 6.99 2.16 81.54 2.10 0.06
Table 5 Output for Hypo1 mapping and predictive model
of test set compounds
Compds IC50 (μM) p(IC50 × 10




B7 47.25 1.33 68.76 1.30 0.03
B8 27.23 1.56 68.78 1.30 0.26
B10 17.88 1.75 74.2 1.58 0.17
D2 8.30 2.08 80.71 1.92 0.16
D3 13.86 1.86 80.39 1.90 -0.04
D4 9.98 2.00 80.56 1.91 0.09
E2 7.76 2.11 80.71 1.92 0.19
F2 12.90 1.89 80.71 1.92 -0.03
H8 40.65 1.39 68.78 1.30 0.09
J4 14.52 1.84 80.56 1.91 -0.07
J8 45.51 1.34 68.78 1.30 0.04
Figure 2 Fit plot of the predicted pIC50 of the training set
compounds with its experimental pIC50.
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model with compounds H5, A6, and I8 as representative
examples. A closer look at the mapped structures revealed
the importance of certain structural features for activity.
The substituted benzene ring of the isatin scaffold is
thought to be critical for activity where the slight displace-
ment of its fused benzene ring away from hydrophobic
pharmacophore center (Figure 4b) or displacement of the
isatin nitrogen away from the hydrogen bond donor
pharmacophore center (Figure 4c) can partially explain
their lack of activity. Furthermore, lack of antiproliferative
activity of the derivatives containing 5-unsubstituted isatin
moiety A1-K1 could be attributed to their missing of
one of the essential hydrophobic pharmacophore cen-
ters (Figure 4c). The rest of the features that are
common for all compounds are the oxygen atom at
2-position of the isatin, the hydrazone nitrogen as
hydrogen bond acceptor, and the hydrazide NH as
hydrogen bond donor.Docking procedure
Docking study was undertaken using Dock6.4 [34] in order
to investigate the possible interactions between the designedFigure 3 Fit plot of the predicted pIC50 of the test set
compounds with its experimental pIC50.compounds and the active site of the epidermal growth
factor receptor (EGFR) kinase and to compare it with the
binding mode of the known EGFR inhibitor N-[4-(3-
bromophenylamino)quinazolin-6-yl]acrylamide
(DJK_3021_ A). The X-ray structure of the enzyme
bounded with DJK_3021_A was taken from the protein
data bank; PDB code: 2J5F [35]. The RMSD value differ-
ence of 1.005 Å of the pose of the non-restricted redocking
of the X-ray structure of the EGFR inhibitor (DJK_3021_A)
from itself also confirmed the approach (Figure 5).
The binding site includes hydrophobic pocket deli-
neated by the side chains of Leu16, Phe21, Val24,
Ala36, Lys38, Glu51, Leu76, Leu80, Cys85, Leu116,
Asp127 (Figure 5).
The docking poses of compound H5, as an example of
the designed compounds (Figures 6 and 7), showed that
isatin scaffold structure is oriented in the binding site as
the same as the quinazoline moiety of the DJK_3021_A X-
ray structure with displacement of the hydrogen bond
acceptor atom in compound H5 from those of the quina-
zoline ring of the DJK_3021_A. The isatin scaffold is
oriented in the hydrophobic pocket surrounded by the
side chains of Leu16, Phe21, Leu80 and Leu116. The
hydrophobic portion of trifluoromethoxy group is overlaid
with the bromophenyl moiety of the DJK_3021_A whereas
it is stabilized between Val24 and Lys38 with the hydro-
phobic interactions. Moreover, hydrophobic aromatic sub-
stituent at nitrogen atom of isatin in H5 is aligned with
the hydrophobic portion of acrylamide substituent of the
DJK_3021_A whereas it is positioned in parallel orienta-
tion between its pi system and Leu116 with additional
hydrophobic interaction between the aromatic ring, of N-
benzoyl moiety, and Phe21 side chain.
Comparing the docking poses of the designed deriva-
tives with DJK_3021_A, it could be postulated that the
designed compounds might act on the same enzyme tar-
get where DJK_3021_A acted.Conclusions
A combinatorial library of 121 Schiff bases of indoline-
2,3-dione (isatin) was investigated for their potential
)b()a( (c)
Figure 4 (a) Best aligned pose of compound H5 (IC50 = 5.88 μM) superposed with the query (Hypo1). (b) Best aligned pose of compound
A6 (IC50> 100 μM) fitted inadequately with the query (Hypo1). (c) Best aligned pose of weak I8 (IC50> 100 μM) overlaid onto the
pharmacophore model (Hypo1).
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with some of these derivatives against K562 chronic
myelogenous leukemia cells with considerable selectiv-
ity compared with the non-tumorigenic MCF-12A cell
line. Pharmacophore modeling study revealed that
these compounds are able to effectively satisfy the pro-
posed common feature sites using energy accessible
conformers (Econf< 20 kcal/mol). Also, docking study
could suggest the similarity in binding mode of the
designed compounds and DJK_3021_A with the EGFR
kinase in its X-ray structure.Experimental
Isatins and hydrazides building blocks were obtained ei-
ther commercially or synthesized along with theFigure 5 N-[4-(3-bromophenylamino)quinazolin-6-yl]acrylamide (DJK_
epidermal growth factor receptor (EGFR) kinase binding site.designed target Schiff bases according to the reported
literatures [26,27,29-31]. Cytotoxicity was done at Stem
Cell Therapy Program, King Faisal Specialized Hospital
and Research Center, Riyadh-Saudi Arabia.Cell cytotoxicity assay
K562 chronic myelogenous leukemia cells were pur-
chased from the American Type Culture Collection.
Cells were maintained in RPMI 1640 (Sigma), supple-
mented with 10% FCS (Cambrex Bio Science), 100 IU/
mL penicillin, 100 mg/mL streptomycin and 2 mmol/
L L-glutamine (Sigma) and were used to investigate the
cytotoxicity of all the synthesized compounds.
MCF-12A cell line is a non-tumorigenic epithelial
cell line established from tissue taken at reduction3021_A) from 2J5F (X-ray magenta, docked white) oriented
Figure 6 Compound H5 (colored Yellow) docked in EGFR binding site and overlaid with DJK_3021_A x-ray structure (colored magenta).
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http://journal.chemistrycentral.com/content/6/1/49mammoplasty from a nulliparous patient with fibrocystic
breast disease that contained focal areas of intraductal
hyperplasia and were used to investigate the cytotoxicity
of all the synthesized compounds.
Cells were seeded into 96-well plates at 0.4*104/well
and incubated overnight. The medium was replaced with
fresh one containing the desired concentrations of the
compounds. After 48 h, 10 μl of the WST-1 reagent
were added to each well and the plates were reincubated
for 4 h at 37°C. The amount of formazan was quantified
using ELISA reader at 450 nm.
Selectivity index (SI)
In the present study, the degree of selectivity of the
synthetic compounds is expressed as per the previousFigure 7 Binding site surface with docked, compound H5
(colored magenta).reports [36,37]: SI = IC50 of pure compound in a normal
cell line/IC50 of the same pure compound in cancer cell
line, where IC50 is the concentration required to kill
50% of the cell population.Molecular modeling
Ligand based pharmacophore modeling
The study was carried out using the software
LigandScout (version 3.0). LigandScout program was
used to derive the 3D chemical feature-based pharma-
cophores from the structural data of the synthesized
compounds (Table 1) using default settings [33].
Compounds A1, A6-A9, B1, B5-B10, C3, C6-C8,
D2-D5, E2, E3, E5, F2, F3, F5, G3, G5, G9, H5, H8,
I3, I8, J4, J5, J8, and K6 are included in the model-
ing method. Prior to the generation of pharmaco-
phore hypotheses, the training set compounds (A1,
A9, B1, B5, B9, C3, D5, E3, E5, F3, F5, G3, G5,
H5, I3, and J5) were converted to 3D structure and
were used to generate diverse conformations. Diverse
Conformation Generation protocol implemented in
LigandScout program was used to generate conforma-
tions using the best conformation model generation
method. Other parameters like maximum number of
500 conformers, and an energy threshold value of
20 kcal/mol above the global energy minimum were
chosen during conformation generation. During
pharmacophore hypothesis generation four pharmaco-
phoric features like hydrogen bond acceptor (HBA),
hydrogen bond donor (HBD), ring aromatic (RA) and
hydrophobic (HY) were selected based on the feature
mapping results. All parameters were set to their de-
fault values.
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The generated pharmacophore hypothesis was validated
using leave-one-out and test set methods.
Leave-one-out method
The pharmacophore hypothesis is cross validated by
leave-one-out method. In this method, one compound is
left in the generation of a new pharmacophore model
and its affinity is predicted using that new model. The
model building and estimation cycle were repeated until
each compound was left out once [38]. This test was per-
formed to verify whether the correlation coefficient of
the training set compounds is strongly depend on one
particular compound or not [39].
Test set method
Compounds B7, B8, B10, D2-D4, E2, F2, H8, J4,
and J8 were selected as test set compounds. This
method is used to elucidate whether the generated
pharmacophore hypothesis is proficient to predict the
activities of the compounds other than training set
and classify them correctly in their activity scale. The
conformation generation for test set compounds was
carried out in a similar way like training set com-
pounds using conformation analysis algorithm. The
compounds associated with their conformations were
subsequently carried out for pharmacophore mapping
using Ligand Pharmacophore Mapping protocol with
Best/Flexible Search option.
Docking procedure
All molecular modeling studies were performed on
PC windows Vista Home Premium Intel(R) Core(TM)
2 Duo, 1.83 GHz using Dock 6.4 [34]. All compounds
were generated in the protonation state under physio-
logical condition. The coordinates of the X-ray struc-
ture of the epidermal growth factor receptor (EGFR)
kinase domain in complex with an irreversible inhibi-
tor DJK_3021_A (PDB code: 2J5F) was taken from
the Protein Data Bank [35]. The co-crystallized ligand
was docked in its original protein structure. Docking
was performed with default settings to obtain a popu-
lation of possible conformations and orientations for
the ligands at the binding site. A 10 Å sphere around
the centre of the binding pocket was defined as bind-
ing pocket for the docking runs. All torsion angles in
each compound were allowed to rotate freely.
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